Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cangene Signs VIG Supply Pact with DoD | Contract Pharma

What are you searching for?

Sign in
Breaking News

Cangene Signs VIG Supply Pact with DoD

The Chemical Biological Medical Systems Project Management Office of the U.S. Department of Defense (DoD) has signed a four-year agreement with Cangene Corp. to purchase its Vaccinia Immune Globulin Intravenous (Human) (VIG) for use by U.S. military perso

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

The Chemical Biological Medical Systems Project Management Office of the U.S. Department of Defense (DoD) has signed a four-year agreement with Cangene Corp. to purchase its Vaccinia Immune Globulin Intravenous (Human) (VIG) for use by U.S. military personnel under the DoD’s Smallpox Immunization Program.The contract is valued at approximately $4.9 million. Cangene expects to deliver the product during fiscal 2010. The DoD has two options to purchase additional product under the contract, which could add approximately $7 million to the total value. Cangene’s VIG product was approved by the FDA in 2005.

“Since this drug was approved, we have signed a number of agreements with government groups to supply product to their stockpiles-this illustrates the benefit of having an FDA license and that there is an ongoing market for the product,” said Dr. John Langstaff, Cangene’s president and chief executive officer.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters